A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
A Shafei, W El-Bakly, A Sobhy, O Wagdy… - Biomedicine & …, 2017 - Elsevier
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer.
A Shafei, W El-Bakly, A Sobhy, O Wagdy… - Biomedicine & …, 2017 - europepmc.org
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
[引用][C] A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
A Shafei, W El-Bakly, A Sobhy, O Wagdy… - Biomedicine & …, 2017 - cir.nii.ac.jp
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy
in metastatic breast cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
in metastatic breast cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
[PDF][PDF] A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
A Shafeia, W El-Baklyb, A Sobhyc… - Biomedicine & …, 2017 - academia.edu
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
A Shafei, W El-Bakly, A Sobhy… - Biomedicine & …, 2017 - pubmed.ncbi.nlm.nih.gov
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
[PDF][PDF] A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
A Shafeia, W El-Baklyb, A Sobhyc… - Biomedicine & …, 2017 - academia.edu
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …
problems due to lack of selectivity with subsequent therapeutic failure and adverse effects …